Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 144

1.

Response of vincristine, melphalan, cyclophosphamide and prednisolone in refractory multiple myeloma.

Kabir AL, Rahman MJ, Begum M, Dipta TF, Baqui MN, Aziz A, Rahman F, Debnath RC, Habib MA.

Mymensingh Med J. 2012 Jan;21(1):114-9.

PMID:
22314465
2.

Superior efficacy of MMCP regimen compared with VMCP and MMPP regimens in the treatment of multiple myeloma.

Mizuno H, Yamao H, Nagura E, Shimizu K, Kamiya O, Takeyama H, Nitta M, Wakita A, Ichikawa A, Kobayashi M, Kawashima K, Saito H; Nagoya Myeloma Cooperative Study Group.

Intern Med. 2002 Apr;41(4):290-4.

3.

Vindesine in refractory multiple myeloma.

van der Lelie H, Monasch E, Pegels HG, von dem Borne AE.

Cancer. 1986 Jan 15;57(2):226-9.

4.

A randomized study comparing VMCP and MMPP in the treatment of multiple myeloma.

Nagura E, Ichikawa A, Kamiya O, Kato R, Utsumi M, Tanaka M, Takeyama H, Shimizu K, Kobayashi M, Naito K, Nishiwaki H, Mizuno H, Hirabayashi N, Nitta M, Kato Y, Shibata T, Hotta T, Kawashima K, Saito H.

Cancer Chemother Pharmacol. 1997;39(4):279-85.

PMID:
9025767
5.

Interferon alfa-2b with VMCP compared to VMCP alone for induction and interferon alfa-2b compared to controls for remission maintenance in multiple myeloma: interim results.

Ludwig H, Cohen AM, Huber H, Nachbaur D, Jungi WF, Senn H, Günczler P, Schüller J, Eckhardt S, Seewann HL, et al.

Eur J Cancer. 1991;27 Suppl 4:S40-5.

PMID:
1799476
6.

VAD followed by VMCP: an alternative regimen for multiple myeloma.

Wadhwa J, Kumar L, Kochupillai V.

Med Oncol. 2002;19(2):105-8.

PMID:
12180477
7.
8.

Marked and sustained improvement of systemic sclerosis following polychemotherapy for coexistent multiple myeloma.

Bachleitner-Hofmann T, Machold K, Knobler R, Drach J, Grumbeck E, Gisslinger H.

Clin Exp Rheumatol. 2002 Jan-Feb;20(1):85-8.

PMID:
11892717
9.
10.

Chemotherapy is superior to sequential hemibody irradiation for remission consolidation in multiple myeloma: a Southwest Oncology Group study.

Salmon SE, Tesh D, Crowley J, Saeed S, Finley P, Milder MS, Hutchins LF, Coltman CA Jr, Bonnet JD, Cheson B, et al.

J Clin Oncol. 1990 Sep;8(9):1575-84.

PMID:
2131793
11.

A randomized trial of melphalan and prednisone versus melphalan, prednisone, cyclophosphamide, MeCCNU, and vincristine in untreated multiple myeloma.

Pavlovsky S, Saslavsky J, Tezanos Pinto M, Palmer L, Curuchet M, Lein JM, Garay G, Dragosky M, Quiroga-Micheo E, Huberman AB, et al.

J Clin Oncol. 1984 Jul;2(7):836-40.

PMID:
6376722
12.

Interferon-alpha-2b with VMCP for induction in multiple myeloma: the Israel Myeloma Cooperative Group experience.

Cohen AM, Meytes D, Many A, Brenner B, Aghai E, Shaklai M, Kaufman S, Shtalrid M, Attias D, Manor Y, et al.

Isr J Med Sci. 1995 Oct;31(10):604-10.

PMID:
7591683
13.

Multiple myeloma: VMCP/VBAP alternating combination chemotherapy is not superior to melphalan and prednisone even in high-risk patients.

Boccadoro M, Marmont F, Tribalto M, Avvisati G, Andriani A, Barbui T, Cantonetti M, Carotenuto M, Comotti B, Dammacco F, et al.

J Clin Oncol. 1991 Mar;9(3):444-8.

PMID:
1999714
14.

Complete remission induction with combined VBMCP chemotherapy and interferon (rIFN alpha 2b) in patients with multiple myeloma.

Oken MM, Kyle RA, Greipp PR, Kay NE, Tsiatis A, Gregory SA, Spiegel R J, O'Connell M J.

Leuk Lymphoma. 1996 Feb;20(5-6):447-52.

PMID:
8833401
15.

[Results of polychemotherapy (a VMCP/VCAP program) in multiple myeloma].

Wutke K, Anger G.

Z Gesamte Inn Med. 1983 Dec 1;38(23):630-3. German.

PMID:
6689459
16.

Continuous prednisolone versus conventional prednisolone with VMCP-interferon-alpha2b as first-line chemotherapy in elderly patients with multiple myeloma.

Ludwig H, Spicka I, Klener P, Greil R, Adam Z, Gisslinger H, Tarkovács G, Linkesch W, Maniatis A, Morant R, Drach J, Kuhn I, Schuster J, Hinke A.

Br J Haematol. 2005 Nov;131(3):329-37.

PMID:
16225652
17.

Combined alpha-2C-interferon/VMCP polychemotherapy versus VMCP polychemotherapy as induction therapy in multiple myeloma: a prospective randomized trial.

Scheithauer W, Cortelezzi A, Fritz E, Kührer I, Polli E, Baldini L, Ludwig H.

J Biol Response Mod. 1989 Apr;8(2):109-15.

PMID:
2659740
18.

Initial treatment in multiple myeloma: no advantage of multidrug chemotherapy over melphalan-prednisone. The Myeloma Group of Western Sweden.

Hjorth M, Hellquist L, Holmberg E, Magnusson B, Rödjer S, Westin J.

Br J Haematol. 1990 Feb;74(2):185-91.

PMID:
2180471
19.

Multi-drug combination therapy with vincristine-melphalan-cyclophosphamide-prednisolone was more effective than cyclophosphamide-prednisolone in stage III myeloma. The Nagoya Myeloma Cooperative Study Group.

Shimizu K, Kamiya O, Hamajima N, Mizuno H, Kobayashi M, Hirabayashi N, Takeyama H, Kato R, Kawashima K, Nitta M, et al.

Jpn J Cancer Res. 1990 Dec;81(12):1320-7.

PMID:
2126002

Supplemental Content

Support Center